Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies

Table 3

Combination therapy approaches in the treatment of EBV malignancies.

Lytic replication inducer	Drug	Target cells	In vivo	Reference
DNA methylase transferase inhibitors
5-Azacytidine	GCV and 5-bromodeoxyuridine	EBV+ and EBV- BL cells	None	Moore et al. [75]
HDAC inhibitors
Arg-Butyrate	GCV	LCL from lung transplant recipient	Single human patient	Mentzer et al. [70]
Arg-Butyrate	GCV		10 human patients	Mentzer et al. [76]
Arg-Butyrate	GCV		15 human patients	Perrine et al. [74]
Valproic Acid*	Cisplatin, 5-FU, Gemcitabine, Doxorubicin	LCL, gastric carcinoma-EBV, NPC	SCID mice	Feng et al. [77]
Na-Butyrate	GCV	P3HR1	None	Ghosh et al. [78]
Radiation
γ-Radiation + Na-butyrate	GCV & AZT	LCL and BL cell lines	SCID mice	Westphal et al. [71]
γ-Radiation	AZT+GCV	LCL-4A1A	Nude rats	Roychowdhury et al. [79]
B-cell receptor blockade
Rituximab+Dexamethasone	GCV	AKATA	Nude mice	Daibata et al. [80]
Proteasome inhibitor
Bortezomib	^131I-FIAU	BL cell line	SCID xenograft	Fu et al. [81]
Other
Cis-platinum, 5-fluorouracil, Taxol	GCV	Gastric carcinoma, NPC	Nude mice	Feng et al. [82]
Gemcitabine and Doxorubicin	GCV	LCL, and BL cell lines	SCID mice	Feng et al. [83]